Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0BW3P
|
|||
Former ID |
DCL000033
|
|||
Drug Name |
Aerovant
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2a | [1] | |
Company |
Aerovance
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Interleukin 4 receptor alpha (IL4R) | Target Info | Antagonist | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
PI3K-Akt signaling pathway | ||||
Jak-STAT signaling pathway | ||||
Hematopoietic cell lineage | ||||
Inflammatory bowel disease (IBD) | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
IL4 Signaling Pathway | ||||
EGFR1 Signaling Pathway | ||||
Panther Pathway | Interleukin signaling pathway | |||
Pathway Interaction Database | p73 transcription factor network | |||
IL4-mediated signaling events | ||||
WikiPathways | Inflammatory Response Pathway | |||
IL-4 Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. | |||
REF 2 | Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.